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Mutation in the Plasmodium falciparum CRT Protein Determines the
Stereospecific Activity of Antimalarial Cinchona Alkaloids
Carol E. Griffin,a* Jonathan M. Hoke,a Upeka Samarakoon,b Junhui Duan,c Jianbing Mu,c Michael T. Ferdig,b David C. Warhurst,d
and Roland A. Coopera,e
Department of Biological Sciences, Old Dominion University, Norfolk, Virginia, USAa; Eck Institute for Global Health, Department of Biological Sciences, University of Notre
Dame, South Bend, Indiana, USAb; Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville,
Maryland, USAc; Department of Pathogen Molecular Biology, Faculty of Infectious and Tropical Disease, London School of Hygiene and Tropical Medicine, London, United
Kingdomd; and Department of Natural Sciences and Mathematics, Dominican University of California, San Rafael, California, USAe
The Cinchona alkaloids are quinoline aminoalcohols that occur as diastereomer pairs, typified by ()-quinine and ()-quini-
dine. The potency of ()-isomers is greater than the ()-isomers in vitro and in vivo against Plasmodium falciparummalaria
parasites. They may act by the inhibition of heme crystallization within the parasite digestive vacuole in a manner similar to
chloroquine. Earlier studies showed that a K76I mutation in the digestive vacuole-associated protein, PfCRT (P. falciparum
chloroquine resistance transporter), reversed the normal potency order of quinine and quinidine toward P. falciparum. To fur-
ther explore PfCRT-alkaloid interactions in the malaria parasite, we measured the in vitro susceptibility of eight clonal lines of
P. falciparum derived from the 106/1 strain, each containing a unique pfcrt allele, to four Cinchona stereoisomer pairs: quinine
and quinidine; cinchonidine and cinchonine; hydroquinine and hydroquinidine; 9-epiquinine and 9-epiquinidine. Stereospe-
cific potency of the Cinchona alkaloids was associated with changes in charge and hydrophobicity of mutable PfCRT amino ac-
ids. In isogenic chloroquine-resistant lines, the IC50 ratio of ()/() CA pairs correlated with side chain hydrophobicity of the
position 76 residue. Second-site PfCRTmutations negated the K76I stereospecific effects: charge-change mutations C72R or
Q352K/R restored potency patterns similar to the parent K76 line, while V369F increased susceptibility to the alkaloids and nul-
lified stereospecific differences between alkaloid pairs. Interactions between key residues of the PfCRT channel/transporter with
() and () alkaloids are stereospecifically determined, suggesting that PfCRT binding plays an important role in the antimalar-
ial activity of quinine and other Cinchona alkaloids.
Alkaloids from theCinchona tree, exemplified by quinine (QN)and quinidine (QD), have proven to be an important source
of antimalarial therapies, especially after resistance to chloroquine
(CQ) emerged. QN remains a first-line drug in the treatment of
severemalaria inmany parts of the world, even with increased use
of artemisinin-based combination therapies (70). The Cinchona
alkaloids (CA) are aryl amino alcohols where the aryl group is a
quinoline (quinoline aminoalcohols). They have four chiral cen-
ters, two of which, C-8 and C-9, can have different configurations
(66) (Fig. 1). Among the pharmacologically active 8,9-erythro iso-
mers, QN, hydroquinine (HQN), and cinchonidine (CD) all pres-
ent the S configuration aroundC-8 and theR configuration at C-9
and are levorotatory (rotate plane polarized light in an anticlock-
wise [] direction). The reverse ordering, R at C-8 and S at C-9,
occurs in the respective dextrorotatory (rotate plane polarized
light in a clockwise [] direction) diastereomers, QD, hydro-
quinidine (HQD), and cinchonine (CN). The 8,9-threo diaste-
reomers 9-epiquinine (EQN) and 9-epiquinidine (EQD) are 8S,
9S, and 8R, 9R, respectively.
Against Plasmodium falciparum, the CA diastereomer pairs
have a well-established in vitro potency order. The dextrorotatory
isomers QD, HQD, and CN have greater antimalarial potencies
than their levorotatory counterparts, QN, HQN, and CD (22, 37,
68). EQN (weakly dextrorotatory) and EQD (dextrorotatory) are
comparatively ineffective; a previous study noted lower efficacies
of approximately 100-fold compared to QN and QD (37). Obser-
vations of stereospecificity extend to in vivo studies on QN and
QD efficacy against P. falciparum, where the latter is the more
potent clinically (62, 69).
The mechanism of action of the quinoline aminoalcohol QN
and the blood schizontocidal 4-aminoquinolines, including CQ,
is believed to depend upon their weakly basic properties that pro-
mote accumulation to high levels in the acidic digestive vacuole
(DV) of intraerythrocytic trophozoite-stage parasites. Once inside
the DV, they presumably bind free heme (monomeric or dimeric
Fe[III] protoporphyrin IX) (1, 18), a toxic intermediate produced
from parasite proteolysis of host hemoglobin (21, 41, 65). Heme
binding is thought to inhibit the formation of the more inert
microcrystalline compound hemozoin, creating a poisonous
buildup of lethal drug-heme complexes (48). Resistance to CQ,
and possibly reduced QN potency, is linked to enhanced efflux of
drug from resistant parasites (40).
Mutations in the pfcrt (Plasmodium falciparum chloroquine
resistance transporter) gene are the primary cause of CQ resis-
tance and also greatly affect QN susceptibility (20, 26). PfCRT, a
protein containing 424 amino acids and 10 predicted transmem-
brane domains (Fig. 2), is thought to be a channel or transporter of
Received 5 September 2011 Returned for modification 10 October 2011
Accepted 30 July 2012
Published ahead of print 6 August 2012
Address correspondence to Roland A. Cooper, roland.cooper@dominican.edu.
* Present address: Carol E. Griffin, Edward Via Virginia College of Osteopathic
Medicine, Blacksburg, Virginia, USA.
Copyright © 2012, American Society for Microbiology. All Rights Reserved.
doi:10.1128/AAC.05667-11
5356 aac.asm.org Antimicrobial Agents and Chemotherapy p. 5356–5364 October 2012 Volume 56 Number 10
the drug-metabolite transporter (DMT) superfamily (43). Al-
though the endogenous function of PfCRT remains enigmatic, its
localization within the DV membrane in trophozoite-stage para-
sites agrees with a role in drug resistance (14). Evidence suggests
that mutated PfCRT, in particular a K76T mutation, confers CQ
resistance by allowing enhanced efflux of CQ from the DV,
thereby reducing the concentration of drug available to bind tar-
get heme (8, 9, 57). However, the cytotoxic properties of CQmay
involve additional PfCRT-related mechanisms beyond DV accu-
mulation (11). Our earlier studies demonstrated that in addition
to producing CQ resistance in P. falciparum, a novel PfCRT K76I
mutation resulted in a dramatic increase in QN susceptibility,
reversing the normally observed potency order of QDQN (14,
26). By taking advantage of the unique antagonistic properties of
verapamil against QN in the K76I mutant clone, we used Schild
analysis (2) to show that PfCRT probably binds QN (16).
The steric and electronic features of the CA that contribute to
the potency of the erythro conformations are believed to impart an
enhanced ability to form intramolecular hydrogen bonds with a
plasmodial receptor(s) (18, 35, 36). Although the presence of such
a target molecule serving as a stereoselective receptor appears ev-
ident in the action of the CA, the nature of this receptor has yet to
be determined. Here, we have tested a panel of eight isogenic par-
asite clones with a series of PfCRT polymorphisms against four
pairs ofCAdiastereomers.Our data show that stereospecific drug-
PfCRT interactions are important determinants of CA potency
against P. falciparum.
MATERIALS AND METHODS
Materials.QN, QD, HQN, HQD, CD, CN, and amantadine (AMT) were
purchased from Sigma-Aldrich Chemical Co. The erythro CA were used
without further purification despite containing up to 5 to 15% of isomers
of the same rotation. EQN and EQDwere kindly provided by G. Reinecke
of Buchler Gmbh, Braunschweig, Germany. Racemic mefloquine (MQ)
was obtained from the Walter Reed Army Institute for Research (Silver
Springs, MD). The ()- and ()-12,11 erythro MQ enantiomers were
synthesized by D. Sturchler at Hoffmann-La Roche, Basel, Switzerland,
and kindly provided by W. Peters (London School of Hygiene and Trop-
icalMedicine). Purity informationwas not available on the 9-epimers and
MQ enantiomers, but 50% inhibitory concentrations (IC50s) against con-
trol P. falciparum lines for these compounds were in agreement with lit-
erature values (37, 38). SYBR green I was purchased fromCambrex Corp.
Drug stocks were prepared to 10 mM in 70% ethanol and maintained at
30°C.
Parasite cultivation anddrug selection.Parasites were cultured using
AB or O red blood cells in complete medium consisting of RPMI 1640
supplemented with 0.5% Albumax I (Invitrogen), 29.8 mM sodium bi-
carbonate, 25 mMHEPES, 0.37 mM hypoxanthine, and 0.01 mg/ml gen-
tamicin and maintained at 37°C under an atmosphere of 90% nitrogen,
5% carbon dioxide, and 5% oxygen. CQ-resistant control parasites Dd2
and 7G8 and the CQ-sensitive HON (parental line of HB3) and 106/1K76
strains were kindly provided by Thomas E.Wellems, National Institute of
Allergy and InfectiousDiseases (Rockville,MD).Drug-resistant lines ofP.
falciparum were selected on the clonal 106/1K76 line by single-step drug
selection (52) as described previously (14, 16). The PfCRT mutants 106/
176N, 106/176T, and 106/176I were selected from 106/1K76 by using 100 nM
CQ. Double PfCRT mutants were generated by an additional round of
single-step selection on cloned 106/176I with either 100 nMQN or 80M
AMT (Table 1). A selection experiment consisted of four individual 150-
cm2 culture flasks containing the desired parent parasite line. Each flask
contained 50 ml of mixed-stage culture with a 5% hematocrit and 5%
parasitemia, representing 109 parasites/flask. Upon reaching 5% para-
sitemia, drug was added at the specified concentration, which was suffi-
cient to rapidly kill all parasites except for any preexisting, drug-resistant
mutants (52). Cultures were maintained for 60 days under drug pressure
and monitored by Giemsa smears for the presence living parasites. Suc-
cessful selections, considered the presence of emergent parasites, occurred
on average once every 10 flasks (14); thus, most four-flask experiments
did not yield mutant lines. All emergent lines were cloned by limiting
dilution (27) prior to DNA sequencing and drug susceptibility testing.
Sequence analysis of pfcrt and pfmdr1 genes. Four randomly chosen
clonal lines were used for pfcrt sequencing from a successful selection
experiment. All open reading frame sequences of pfcrt were amplified
FIG 1 Chemical structures of CA and MQ stereoisomers used in this study.
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from P. falciparum genomic DNA (63). From clonal lines chosen for fur-
ther study, the entire open reading frame of pfmdr1, or known polymor-
phic regions of pfmdr1, were amplified from genomic DNA using primers
described previously (44, 51). PCR products were directly sequenced us-
ing an ABI 3730xl DNA analyzer (Applied Biosystems).
Determination of pfmdr1 copy number by real-time PCR. The copy
number of pfmdr1was estimated in mutant lines of P. falciparum by Taq-
Man real-time PCR using an ABI 7900HT Fast real-time PCR system as
described previously (54). Assays were conducted in four independent
replicates and normalized to HB3 genomic DNA, which was included in
every run. The copy number for 7G8 was from Sa et al. (54a).
Drug response assays. The in vitro susceptibility of P. falciparum to
the CA was measured in a 72-h, 96-well microplate fluorescence assay
using SYBR green I detection as described previously (6, 61). Parasites
were introduced into the drug assay at48-h intervals until at least three
independent replicates were performed. Mean half-maximal inhibitory
concentrations (IC50s) were derived by plotting the percent growth inhi-
bition against the log drug concentration and fitting the response data to
a variable slope, sigmoidal curve-fit function for normalized data by using
Prism 5.0d forMacintosh (GraphPad Software). IC50s representmeans
standard errors of the means (SEM) from 3 to 8 independent tests. Rele-
vant IC50s between respective mutant and parental lines were tested for
statistically significant differences by an F test to determine whether two
dose-response data sets were best described by single or independent
curve fits (P 0.05).
Correlation of PfCRT position 76 amino acid hydropathy with ()/
() CA IC50 ratios.Hydropathy values at pH 5.0 for themutable position
76 residues N, T, and I were those described in reference 39. Because the
hydropathy value for N was assigned a 0 (39), an arbitrary value of 4 was
added to each coefficient to accommodate log transformation. Log hy-
FIG 2 Topographic representation of PfCRT. Arrows and clear circles indicate polymorphic amino acids described in this study. PfCRT contains 424 amino
acids and has 10 predicted transmembrane domains (43).
TABLE 1 PfCRT haplotypes, geographic origins, and CQ susceptibility profiles of P. falciparum lines used in this studya
Parasite Origin Selectionb CQc Dayd
Variable PfCRT amino acids PfMDR1e
72 74 75 76 220 271 326 352 356 369 371 Allele CN
HON Honduras S C M N K A Q N Q I V R NFSDD 1
7G8 Brazil R S M N T S Q D Q L V R NFCDY 1
Dd2 Thailand R C I E T S E S Q T V I YYSND 3
106/1K76 Sudan S C I E K S E S Q I V I YYSND 2
106/176N Lab CQ R 42 C I E N S E S Q I V I YYSND 2
106/176T Lab CQ R 33 C I E T S E S Q I V I YYSND 2
106/176I Lab CQ R 28 C I E I S E S Q I V I YYSND 1
106/172R-76I Lab CQ-QN S 37 R I E I S E S Q I V I YYSND 1
106/176I-352R Lab CQ-QN S 32 C I E I S E S R I V I YYSND 1
106/176I-352K Lab CQ-QN S 34 C I E I S E S K I V I YYSND 2
106/176I-369F Lab CQ-AMT I 42 C I E I S E S Q I F I YYSND —f
a Lines were derived from 106/1K76 by single-step drug selection as described in Materials and Methods. Shaded boxes indicate mutant amino acids selected in this work relative to
106/1K76.
b Drug(s) used to select the indicated mutant line by single-step selection. All double mutant lines were generated from the CQ-selected single mutant line 106/176I. Listed after CQ
is the drug used in the second round of single-step selection.
c R, CQ resistant; S, CQ sensitive; I, CQ intermediate.
d Day at which mutant parasites were first observed in culture.
e Amino acid residues at known polymorphic PfMDR1 positions 86, 184, 1034, 1042, and 1246. CN, pfmdr1 copy number, as determined by real-time PCR.
f —, no data.
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dropathy was plotted against the log ()/() IC50 ratios for all alkaloid
pairs (QN/QD, HQN/HQD, CD/CN, and EQN/EQD). Using the same
drug susceptibility data described above, log IC50 ratios (n of 3 to 6) were
calculated from respective CA IC50 pair data fromwithin individual assay
plates. Log ratio data were averaged and plotted,  SEM, for each CA
diastereomer pair. Linear regression was performed using the GraphPad
Prism 5.0 software. The slope value of the linear fit was tested for a statis-
tical difference from zero (P 0.05).
RESULTS
Selection of PfCRT mutant lines of P. falciparum. PfCRT mu-
tant parasites were selected from the CQ-sensitive parental line
Sudan 106/1 (designated 106/176K here) (4, 14, 16). This parasite
strain is appropriate for single-step drug selection studies, as
the pfcrt allele contains all mutations necessary for CQ resistance
other than the single critical point mutation that results in the
K76T polymorphism (14, 16, 26) (Table 1). The selection of all
mutants reported here, except 106/176I-369F, has been described in
detail elsewhere (14, 16). Western blotting demonstrated similar
expression levels of PfCRT from these parasite lines (16), and
nucleotide sequencing demonstrated that no mutations were se-
lected in pfmdr1 (Table 1). In the absence of drug pressure, all
measured drug phenotypes have remained stable in long-term
cultures (6 months). In addition to the clone presented in this
report, the 106/176I line has been selected on multiple indepen-
dent occasions, each time producing identical phenotypes to all
drugs tested, providing strong evidence for the role of the PfCRT
mutation in the CA responses (14, 16, 26). Finally, transfection of
the K76I PfCRT allele into the GC03 line of P. falciparum resulted
in similar drug responses to 106/176I, despite the differing genetic
background of the recipient parasite line and greatly reduced ex-
pression levels of transgenic PfCRT (60).
AMT shows a strong inverse potency relationship with CQ
against P. falciparum and has been previously used for the selec-
tion of novel PfCRTmutations inCQ-resistant parasites (34).Our
AMT-resistantmutant was generated by single-step selectionwith
CQ on 106/1K76 to generate 106/176I, followed by an additional
round of single-step selection with 80 M AMT to generate an
AMT-resistant parasite. Parasites were first observed in culture
after 42 days of continuous AMTpressure, and emergent parasites
were found to possess a novel V369F PfCRT mutation (Table 1)
predicted to occur in the DV loop between transmembrane do-
mains 9 and 10 (43) (Fig. 2). Once cloned, drug susceptibility
assays showed that 106/176I-369F had become90-foldmore resis-
tant to AMT, with an IC50 of 387 20M, compared to 4.4 0.3
M for the 106/176I parental line. The doublemutant also became
nearly 5-fold more susceptible to CQ after acquiring the V369F
mutation (Table 2).
Parasite susceptibility to the CA is associated with PfCRT
polymorphisms. In earlier studies, we demonstrated that a PfCRT
K76I mutation greatly increased susceptibility to QN but not to
QD, resulting in a reversal of the normal isomer potency order,
where QD is 2- to 4-fold more potent than QN (14). To further
characterize the relationship between PfCRT and the three-di-
mensional structure of CA, we measured the in vitro potency of
four diastereomer alkaloid pairs against a set of pfcrtmutant par-
asite clones derived from the 106/1K76 strain (Table 1). The result-
ing IC50s showed that, among the pharmacologically active erythro
alkaloids, the dextrorotatory () QD, HQD, and CN (8R, 9S)
were 1.7- to 7.7-fold more potent than the levorotatory () QN,






































































































































































































































































































































































































































































































































































































































































Stereospecificity of the Cinchona Alkaloids
October 2012 Volume 56 Number 10 aac.asm.org 5359
clones, with the exception of 106/176I and 106/176I-369F (Table 2).
Among the CQR pfcrtmutants, trends emerged that ()/() IC50
ratios increased (76N and 76T) or decreased (76I) relative to the
original 106/1K76 parent line.
These increased potency differences were primarily due to the
selective change in susceptibility to either the () or () diaste-
reomer, depending on PfCRTmutation. Relative to 106/1K76 par-
ent, in the 106/176T line, which carries the K76T mutation ubiq-
uitously observed in CQ-resistant field isolates, a decreased
susceptibility to the ()-isomers QN, HQN, and CD and to the
weakly () EQN was observed. Little effect was seen on response
to the ()-isomers, except for a slight loss in sensitivity to HQD.
In contrast, the 106/176N line primarily showed increased suscep-
tibility to the ()-isomers QD, HQD, CN, and () EQD, with
some loss of sensitivity to the ()-isomer HQN and the weakly
() EQN. Most notably, against 106/176I we observed a selective
increase in potency of the ()-isomers up to 7-fold compared to
the 106/1K76 line. Only a slight increase in potency was observed
for the ()-isomers QD and CN, and no change was observed
with HQD. In sum, the selective increase in susceptibility to the
()-isomers by 106/176I resulted in a reversal of the normally
reported potency order of QN  QD and HQN  HQD. The
effect on the CD/CN pair was less dramatic. Although relative CN
potency diminished 2.5 times to 1.4 times more than CD, the
potency order remained in keeping with the parent line (Table 2).
Because of the great sensitivity of 106/176I toQN (IC50, 19 nM),
we previously used single-step QN pressure to select three addi-
tional PfCRT mutants from this line: 106/172R-76I, 106/176I-352K,
and 106/176I-352R (Table 1) (16). These double mutants all ac-
quired a positively charged lysine or arginine in substitution for a
neutral residue, while retaining the 76I residue. As expected, all
three lines showed elevated QN IC50s compared to 106/1
76I, yet
they also became sensitive to CQ (16). Accompanying the increase
in the QN IC50, the double mutants had parallel increases in IC50s
for the other ()-isomers, CD and HQN, ranging from 2.3- to
5.6-fold. Comparatively little effect was seen on IC50s for the ()-
isomers QD, CN, and HQD following selection of the position 72
or 352 mutations. These results show that the secondary muta-
tions at PfCRT position 72 or 352 abrogated the stereoselective
effect of the K76I mutation on the CA. Among these double mu-
tants, no clear trends were observed in drug susceptibilities, other
than a slightly elevated QN response in 106/176I-352R (Table 2).
Relative to the 106/176I parent line, AMT-selected 106/176I-369F
was more susceptible to all the erythro CA, with the exception of a
slight increase in the QN IC50 (Table 2). While no clear trends
were observed among isomers, potency differences between di-
astereomer pairs were largely abrogated by the V369F mutation.
Three reference control strains, Dd2, 7G8, and HON, were
chosen for this study based on their diverse PfCRT haplotypes and
CQ susceptibility profiles (26) (Table 1). Predictably, the dextro-
rotatory isomers QD,HQD, and CNhad greater in vitro potencies
than the levorotatory QN, HQN, and CD against these lines (Ta-
ble 2). The CQ-sensitive HON strain showed increased sensitivity
to all CA tested, other than QN, compared to the CQ-resistant
controls 7G8 and Dd2. The Dd2 and 106/176T lines both carry the
K76T mutation ubiquitously found in CQ-resistant isolates, dif-
fering only by a threonine-to-isoleucine substitution at PfCRT
position 356 (15). Not surprisingly, the responses for the two lines
were similar for all CA. The minor inherent differences in IC50s
may be attributed to both the position 356 PfCRT amino acid
change (Table 1) and also genetic background differences.
Compared to the erythro alkaloids, the threo alkaloids EQNand
EQD were previously shown to be about 10 to 100 times less po-
tent against CQ-resistant andCQ-sensitive strains, respectively, of
P. falciparum (37).With one exception, 106/176I-369F, we observed
similarly weak activity, although there were clearly response
changes to EQN and EQD associated with PfCRTmutations. The
South American line 7G8, which contains a unique CQ-resistant
PfCRT haplotype compared to Dd2 and HON, was significantly
(P  0.05) more resistant to both 9-epimers (Table 2). The only
apparent trendswere observed among the double PfCRTmutants.
The double mutants were all significantly more sensitive to EQN
andEQD than either the singlemutant 106/1K76 or 106/176I parent
lines. EQNwas slightly more potent than EQD against the double
mutants, while the potency order varied with no obvious trend
revealed among the other lines. Surprisingly, 106/176I-369F became
9- to 16-fold more susceptible to the normally weakly active
9-epimers relative to 106/176I, with EQN displaying nearly 4-fold
greater potency than EQD. Based on the weak activity of the
9-epimers against the other parasite lines, it was unlikely that the
large increase in potency against 106/176I-369F was due to impuri-
ties consisting of the active erythro alkaloids.
Among theCQ-resistantmutants, PfCRThydropathy is cor-
related with CA ()/()-isomer IC50 ratios. Earlier, we demon-
strated that among CQ-resistant clones derived from 106/1K76, a
positive correlation exists between the CQ IC50 and hydrophobic-
ity of the PfCRT position 76 residue (16). Therefore, we examined
the hydropathy of these same residue side chains in relation to the
differential effects of the CA isomers. Hydropathy values of amino
acid side chainswithin a standardized synthetic polypeptide struc-
ture were determined at pH 5.0 by Kovacs et al. (39). This pH
value is within the measured pH range for the P. falciparum DV
lumen (5, 28), where the PfCRT position 76 amino acid is pre-
dicted to face (Fig. 2) (43). Log IC50 ratios for all four CA pairs
were plotted against log-transformed hydropathy values for N, T,
and I residues corresponding to the CQ-selected mutants (Fig. 3).
The log ()/()-isomer ratios clearly decreased as the PfCRT
position 76 residue becomes more hydrophobic (P 0.0001) for
all CA pairs. We also conducted a t test between themean log IC50
ratios of the N and T residue, as the I value could leverage the
regression due to its more extreme position on the plot. All N
versus T mean log IC50 ratios were significantly different (t test, P
 0.05), except for the CD/CN pair, which differ from the other
CA in their lack of the quinolinemethoxy group. Inclusion of data
from the geographically disparate 7G8 and Dd2 lines reduced the
significant difference between 76N and 76T CA ratios (t test, P
0.05), possibly due to influences of the different pfcrt alleles and in
other genetic loci on drug susceptibility (24).
CA phenotypes are independent of polymorphisms or gene
copynumber changes in pfmdr1.The entire pfmdr1 open reading
frame from the 106/1 parasite set was sequenced, except for 106/
176I-372R and 106/172R-76I, where sequencingwas limited to regions
flanking and including the key polymorphic codons 86, 184, 1034,
1042, and 1246. No changes were detected in the sequence of any
of the mutant parasites relative to the parental 106/1K76. All lines
contained an identical pfmdr1 allele (YYSND),with onemutation,
N86Y, relative the “wild-type” allele (NYSND) (Table 1).
The copy number of the pfmdr1 gene was assessed in seven
mutant lines by using quantitative real-time PCR (Table 1). The
Griffin et al.
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parental 106/1K76 line was determined to have two copies of
pfmdr1. Following drug selection, 106/176I was found to have one
copy, while 106/176N and 106/176T remained with two copies.
Double mutants, selected from 106/176I, were single copy, except
for 106/176I-352K, which had reverted to the original two copies of
pfmdr1. No apparent trend was observable between CA responses
and pfmdr1 copy number.
Potency order of ()- and ()-MQ isomers unchanged by a
PfCRT K76I mutation but altered by a secondary V369F muta-
tion. It has been shown that the enantiomers of MQ, a synthetic
quinoline aminoalcohol analog of QN and QD (Fig. 1), also pos-
sess differential activities against P. falciparum. The ()-isomer of
MQ, shown to be the stereo-equivalent of QD in terms of absolute
conformation, reportedly has 1.7 to 1.8 times greater activity than
()-MQ, the QN equivalent (36, 38). We tested 106/1, 106/176I,
and 106/176I-369F (Table 3) in drug assays to determine if the un-
usual effects of these PfCRTmutations on the CAwas extended to
the structurally similar MQ isomers. We observed a potency in-
crease in both MQ enantiomers associated with the PfCRT K76I
mutation, consistent with the increase in potency of racemic MQ
that we reported earlier against this clone (14). We found that
()-MQ was 1.6 times more potent than ()-MQ against the
106/1K76 parent line and 2.6 times more potent against 106/176I.
Thus, despite the presence of a PfCRT mutation that imparts ste-
reospecific changes to CA activity, the difference in MQ isomer
potency order was unchanged from the 106/1K76 parent line, as
well as from that of parasite isolate data reported from earlier
studies (38). In contrast, isomer potency differences were lost
against 106/176I-369F, consistent with observations of this line
against the erythro CA. It is possible that the loss of a pfmdr1 copy
(Table 1) contributes to the increase in MQ susceptibility by 106/
176I compared to the parent line. MQ responses are closely linked
to pfmdr1 copy number changes (17, 58).
DISCUSSION
In P. falciparum, polymorphisms in the PfCRT protein confer CQ
resistance and profoundly influence susceptibility to QN and QD
(14, 26). The pfmdr1 gene, encoding a P-glycoprotein-like ABC
transporter, can also modulate CQ and QN responses through
mutations and changes in gene copy number (53, 58, 59). Re-
cently, polymorphisms in a P. falciparum-encoded Na/H ex-
changer, PfNHE-1, were linked to in vitro QN susceptibility in
laboratory-adapted and clinical isolates in some studies, but not in
others (3, 10, 24, 31, 50). Neither mutations in pfnhe-1 or pfmdr1
nor gene copy number in the latter are known to influence ste-
reospecific responses to CA (7, 24, 49, 59). Our findings support
PfCRT as a major parasite-encoded determinant of CA suscepti-
bility and stereospecificity, although additional genes, gene inter-
actions, and other genomic changes likely contribute parasite re-
sponses to the CA (24, 33).
Although no effects on CA responses were discernible, a
pfmdr1deamplificationwas seen in some 106/1mutants (Table 1),
resulting from the reduction from two gene copies to one in the
106/176I line. Many studies have shown that pfmdr1 expression
levels are associated with P. falciparum susceptibility to QN, al-
though the relationship is dependent on the genetic background
of the parasite (55). Indeed, QN responses were not associated
with pfmdr1 copy number in other recent in vitro and in vivo
studies (12, 13), nor is there evidence of linkage of QN responses
with copy number among progeny in the HB3  Dd2 genetic
cross (24; M. T. Ferdig, unpublished data). While the increased
QN susceptibility of 106/176I may be in part attributed to the loss
of a pfmdr1 gene copy, transfection studies have shown that the
K76I pfcrt allele also confers a similar phenotype (60).
The stereoselective pharmacological properties of QN and QD
have been documented against several classes of bacterial and
mammalian transporters (29, 30, 32, 46, 47), underscoring the
importance of drug-receptor binding in their mechanisms of ac-
tion. Against P. falciparum, the CA ()-isomers are normally
more potent than the (–)-isomers, and evidence points to the
necessity of drug-heme binding in their mechanism of action (1,
21, 45). Compared to QN, QD may possess a greater binding
affinity for heme monomer under both aqueous and aprotic con-
ditions andmore potently inhibit	-hematin (the synthetic equiv-
alent of hemozoin) formation (1, 18), providing a plausible expla-
nation for the greater potency of the ()-isomers. However,
analysis of additional CA and other QN analogs failed to establish
a clear correlation between drug-heme binding affinity, inhibition
of 	-hematin formation and in vitro potency (1). Observed ste-
reospecific changes in the CA response could also be a conse-
TABLE 3 Effects of PfCRT K76I and V369F mutations on susceptibility
to ()- and ()-MQ stereoisomers
Drug
IC50 (nM) in parasite line
a
106/1K76 106/176I 106/176I-369F
()-MQ 13.5 0.7 2.3 0.3* 3.3 0.3†
()-MQ 21.2 1.0 5.9 0.9* 3.4 0.3†
[()()]b MQ 18.3 1.0 5.1 0.7* 3.4 0.3†
MQ (racemic) 14.4 1.3 3.1 0.4* 3.1 0.3
a Values are means SEM derived from 3 independent assays. *, significantly different
average IC50 from 106/1
K76 parent line (F test; P 0.05); †, significantly different
average IC50 from 106/1
76I parent line (F test; P 0.05).
b A 50/50 mixture of the ()- and ()-isomers.
FIG 3 ()/() CA IC50 ratios correlate with pH 5 hydropathy coefficients of
PfCRT position 76 residues from CQ-resistant mutants of 106/1K76. The log
()/() IC50 ratios of the four CA pairs were plotted as a function of the
log(hydropathy coefficient  4), as described in reference 39. Error bars
represent SEM of the average within-plate IC50 ratios as described in Ma-
terials and Methods. The slopes of the regression lines were as follows: for
QN/QD, y
1.13x 1.29, and R2
 0.94; for HQN/HQD, y
1.29x
1.22 and R2 
 0.93; for CD/CN, y 
 0.60x  1.02 and R2 
 0.89; for
EQN/EQD, y 
 0.55x  0.53 and R2
 0.90. All slopes values are signif-
icantly different from zero (P  0.0001). Average log()/() IC50 ratios
were also compared for N versus T by t test, to control for a disproportion-
ate effect on the regression by the more extreme hydropathy coefficient of
I (see Results). Letter abbreviations for the corresponding PfCRT position
76 amino acids are shown adjacent to the data points on the graph.
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quence of altered drug-heme binding in the DV due to changes in
the chemical environment imparted by mutant PfCRT. Based on
the differences in the quinoline N pKa of QN and QD, it was
predicted that subtle changes in DV pH, such as a putative in-
creased acidity related to PfCRT mutations, can significantly in-
crease accumulation of the () diastereomer QD (41). However,
this theory is inconsistent with the measured (and albeit contro-
versial) decrease in DV pH in 106/176I and the selective increase in
sensitivity to QN and the other (–) diastereomers (6, 14).
The hydropathy of certain mutable PfCRT residues shows
quantitative relationships with susceptibility to CQ and desethy-
lamodiaquine (16, 64). Among the CQ-resistant 106/1 mutants,
the patterns of CA susceptibility suggest complex interactions be-
tween the physicochemical features of the drug and the three-
dimensional and chemical environment of the PfCRT pore. This
was further investigated by plotting (–)/() CA IC50 ratios in
relation to PfCRT amino acid 76 hydropathy. A clear log-log cor-
relation was found between the IC50 ratios for all four CA pairs
and residue 76 hydrophobicity (Fig. 3), indicating that the striking
effect on diastereomer sensitivity by the K76I mutation (14, 16) is
not unique. The loss-of-chargemutationsmay increase the poten-
tial for hydrophobic interactions with some quinolines, suggest-
ing greater drug access to the PfCRT channel in CQ-resistant iso-
forms. In the case of K76, since the diastereomer pairs are
practically mirror images, an attractive explanation of stereospe-
cific drug susceptibility is that the positively charged lysine sees
first the hydrophobic side of QN (perhaps involving the aromatic
quinoline ring and methoxy group); no interaction occurs and a
proportion of drugmolecules escape theDV. ForQD,K76 sees the
hydrophilic positively charged quinuclidine ring first and QD is
repelled from entering the transporter, and it is thus retained in
the DV to a greater extent. Along with drug molecule bulk that
also determines the stringency with which a binding site distin-
guishes between (–) and () isomers, this could account for the
general superiority of dextrorotatory CA against CQ-sensitive
strains and the K76T and K76N mutants. CA susceptibility may
also result from PfCRT binding (16) and subsequent inhibition of
the endogenous function of the transporter itself (56). The differ-
ent IC50s that accompany the PfCRT amino acid changes could
therefore reflect relative CA-receptor binding affinities, which in
turn may dictate DV drug accumulation levels and heme-binding
equilibrium.
In contrast to the wide range in CA susceptibility among the
CQ-resistant parasite lines, the control line, HON, and the CQ-
sensitive pfcrt mutants showed very similar responses to the
erythro CA. The positive charge of a key lysine or arginine residue
in either transmembrane domain 1 or 9 of these lines (16) may
reduce binding with CA due to electrostatic repulsion, and in
keeping with this action, reduce the interactions responsible for
stereospecificity. In the acidic DV (pH, 5.2), the CA will be
mostly in themonoprotic formdue to protonation of the aliphatic
nitrogen (66). This similarity in IC50s exists alongside three poly-
morphisms in the HON PfMDR1 (Y86N, Y184F, and N1042D)
(49) relative to 106/1K76, emphasizing the dominant role of the
wild-type PfCRT transporter in CA susceptibility.
Our results demonstrate that a PfCRT position 76I residue in
combination with a second-site mutation leads to a significant
increase in the activity of the threo 9-epimers against P. falciparum
(Table 2). Results from crystallographic studies suggested that,
due to their rotational conformation, the 9-epimers are unable to
form the same intramolecular hydrogen bond with the heme pro-
pionate as do the active erythroCA, resulting inweak potency (18).
These data are consistent with observations that neither EQD nor
EQN, in contrast to the erythro CA, inhibit 	-hematin formation
in vitro (1, 21, 66). Additionally, the reduced lipid-aqueous
distribution coefficients of the 9-epimers due to the higher pKa
values of the quinuclidine aliphatic nitrogen compared to that
of the erythro CA are predicted to reduce solubility in the par-
asite membrane by a factor of 12.6 (66). Further studies are
needed to determine if the K76I PfCRT double mutants retain
more of the threo CA in the DV than do the other mutant lines.
An earlier study identified the vacuolar loop between putative
transmembrane domains 9 and 10 as part of the PfCRT-binding
site for AzBCQ, a CQ analog and photoaffinity label (42). Binding
of the affinity label was competitively inhibited by QN, suggesting
overlap in their respective binding sites. These results are consis-
tent with our observations here, as the PfCRT V369F change oc-
curs within this same loop region (Fig. 2) and is associated with
increased susceptibility to the CA and CQ (Table 2). We propose
that the bulky, rigid, and hydrophobic 369F side chain sterically
hinders the ability of quinolines to escape the DV through the
PfCRT pore, or it may serve as an alternative hydrophobic CA
binding site to 76I where the CA drugs are less sterically con-
strained, in this case in theDV lumen. Steric constraint by 369F on
the exit of CQ from the DV is also plausible, as hydrophobic in-
teractions are unlikely since CQ is doubly protonated at DV and
cytoplasmic pH values (25).
The synthetic quinoline aminoalcohol derivative MQ retains
equivalent chiral centers (C-12 and C-11) to C-8 and C-9 of the
CA (36) (Fig. 1). Superposition of ()-MQwithQDshowed iden-
tical positioning of the quinoline rings, amine, and hydroxyl
groups for the two compounds. Favorable orientation of the ali-
phatic amine and hydroxyl groups for hydrogen bonding with a
malaria receptor has been proposed to explain the potency advan-
tage of ()-MQ or QD over the respective enantiomer or diaste-
reomer (38). Unlike the pronounced effects on the CA, drug as-
says with ()- and (–)-enantiomers of MQ against 106/176I and
106/176I-369F showed little effect onMQpotency order (Table 3). It
is of note that, in contrast to threoCA, the racemate of 12, 11 threo
MQ is as potent as the racemate of 12, 11 erythro mefloquine
against Plasmodium berghei and P. falciparum in vitro (38, 67).
This difference reflects the increased ease of rotation around the
link between the asymmetric carbon atoms due to the lower bulk
of the piperidine ring as opposed to that of quinuclidine (36, 67).
The bulkier quinuclidine side chain of the CAmay contribute to a
loss of flexibility, imparting a structural constraint that may con-
fer the greater stereospecificity of theCA than the other quinolines
(19). Alternatively, as MQ is a substrate for PfMDR1 (23), ste-
reospecificitymay be determined by interactions with this protein
or heme, and not by PfCRT. Transfection studies with the K76I
PfCRT allele, and pfmdr1 knockdown experiments clearly support
a role for both transporters in the increased sensitivity to MQ by
106/176I (58, 60).
Taken together, our data suggest that the well-established po-
tency order of QD  QN is dictated by the PfCRT haplotypes
found in CQ-sensitive (K76) and -resistant (K76T) field and lab
isolates. In CQ-sensitive parasites, electrostatic repulsion between
critical lysine/arginine residues (position 72, 76, or 352) and CA
may prevent these drugs from participating in stereospecifically
determined hydrophobic interactions but apparently allowsmore
Griffin et al.
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repulsion of () diastereomers. Mutant parasite lines with alter-
native 76N/T/I side chains reveal distinct stereospecific interac-
tions with CA, indicating greater access of the drug to stereo-
determining residues in the CQ-resistant forms of the PfCRT
channel. These highly specific interactions implicate PfCRT as a
receptor or binding site for the CA. Binding may dictate drug
potency by determining CA accumulation levels in the DV or by
interfering with the endogenous function of PfCRT (56). Studies
with the purified transporter will be necessary to confirm if PfCRT
itself serves as a drug target for CA.
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